Hematology

Chronic Lymphocytic Leukemia

Previously Treated

Age > 18

Previously Untreated

Age > 18

HEMCLL0024
Phase III
Open-Label
Randomized Study of Pirtobrutinib (LOXO-305) vs Ibrutinib in Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

PI: Fakhri
Sponsor: Loxo Oncology, Inc.

HEMCLL0025
Chronic Lymphocytic Leukemia (CLL) Collaborative Study Of Real-World Evidence (CORE)

PI: Fakhri
Sponsor: AbbVie Inc.

HEMCLL0026
First-in-Human Study to Evaluate Safety Pharmacokinetics & Preliminary Efficacy of the BTK Degrader, ABBV-101, in B-Cell Malignancies

PI: Fakhri
Sponsor: AbbVie Inc.

HEM0063
Phase Ib/II, Open-Label, Safety and Efficacy Study of Ezucalitumab (GEN3013, DuoBody®-CD3 X CD20) in Relapsed / Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

PI: Fakhri
Sponsor: Genmab Collaborator: AbbVie

HEMCLL0026
Phase Ib/II, Open-Label, Safety and Efficacy Study of Epoptitamab (GEN3013, DuoBody®-CD3 X CD20) in Relapsed / Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

PI: Fakhri
Sponsor: Genmab Collaborator: AbbVie

HEMCLL0028
Phase II Venetoclax-Based Therapy for the Treatment of Fit Patients with Chronic Lymphocytic Leukemia (CLL) in the Front-Line Setting

PI: Fakhri
Sponsor: Memorial Sloan Kettering

KEY

Pending
Open for Enrollment
Observational Study
Optional Path
Link
Enrollment on Hold
Trial Posting

Extension Study
Immunotherapy

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu